On September 19, 2024, GC Therapeutics (GCTx), a biopharmaceutical company created to scale and unlock the next generation of cell therapy-based medicines, launched and announced the successful completion of a $65 million Series A financing led by Cormorant Asset Management with participation from Mubadala Capital, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management, and Pear VC, bringing the total capital raised by GCTx to $75 million. Wilson Sonsini Goodrich & Rosati advised GC Therapeutics on the transaction.

GCTx’s proprietary induced pluripotent stem cell (iPSC) programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), integrates the latest advancements in synthetic biology, gene editing, cell engineering, and machine learning to improve patient access and overcome the development and scaling challenges of cell therapy. The platform could produce off-the-shelf cell therapies up to 100 times more quickly than conventional methods.

The Wilson Sonsini team that advised GCTx on the transaction includes Mark Fitzgerald, Leah Hengemuhle, and Aaron Gordon.

For more information, please see GCTx's news release. Additional coverage can be found on FierceBiotech, Chemical & Engineering News, and BioPharma Dive.